Nuformix Plc (GB:NFX)
LSE:NFX
Want to see GB:NFX full AI Analyst Report?
NFX Stock Chart & Stats
0.23 p
<0.01 p(2.11%)
At close: 4:00 PM EST
0.23 p
<0.01 p(2.11%)
Day’s Range― - ―
52-Week Range0.07 p - 0.56 p
Previous CloseN/A
Volume1.00M
Average Volume (3M)97.88M
Market Cap
£4.31M
Enterprise Value3.49M
Total Cash (Recent Filing)£97.55K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Dec 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,609,750,000
10 Day Avg. Volume69,476,590
30 Day Avg. Volume97,880,797
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-6.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Cocrystal PlatformA proprietary cocrystal platform is a durable competitive asset: it enables multiple reformulations across molecules, supports licensing/partnership models, and shortens development risk versus new chemical entities, underpinning recurring R&D and commercial opportunities.
Very Low LeverageZero debt materially reduces financial risk and interest burden, giving management flexibility to pursue partnerships, licensing or future financings without heavy fixed obligations, improving survivability through product development cycles.
Lower Loss In 2025A materially smaller 2025 loss versus 2024 implies management has tightened costs or removed one-offs; if maintained, this can extend runway, improve chance of reaching commercialization milestones and reduce dependency on urgent financing.
Bears Say
No Recent RevenueThree consecutive years without meaningful revenue indicates a stalled commercialization profile and that core technology has yet to produce sustainable product sales, forcing reliance on development funding and licensing to validate long-term viability.
Consistent Cash BurnPersistent negative operating and free cash flow signals structural cash burn; absent revenue, the company must repeatedly access external capital, increasing dilution risk and creating execution risk if funding markets tighten over the medium term.
Shrinking Equity And AssetsA materially smaller equity and asset base reduces financial buffer against setbacks, limits ability to invest in multiple programs simultaneously, and heightens the risk that a single development failure or funding delay could jeopardize operations.
Nuformix Plc News
NFX FAQ
What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest share price was 0.07 p and its highest was 0.56 p in the past 12 months.
What is Nuformix Plc’s market cap?
Nuformix Plc’s market cap is £4.31M.
When is Nuformix Plc’s upcoming earnings report date?
Nuformix Plc’s upcoming earnings report date is Dec 15, 2026 which is in 208 days.
How were Nuformix Plc’s earnings last quarter?
Nuformix Plc released its earnings results on Jan 27, 2026. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is Nuformix Plc overvalued?
According to Wall Street analysts Nuformix Plc’s price is currently Overvalued.
Does Nuformix Plc pay dividends?
Nuformix Plc does not currently pay dividends.
What is Nuformix Plc’s EPS estimate?
Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuformix Plc have?
Nuformix Plc has 2,609,750,000 shares outstanding.
What happened to Nuformix Plc’s price movement after its last earnings report?
Nuformix Plc reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -15.751%.
Which hedge fund is a major shareholder of Nuformix Plc?
Currently, no hedge funds are holding shares in GB:NFX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuformix Plc
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Technical Analysis
Evgen Pharma
―
Futura Medical
―
ImmuPharma
―
OptiBiotix Health
―
HemoGenyx Pharmaceuticals Plc
―